Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II immunogenicity and safety study of a recombinant zoster vaccine (CHO cells) in adults aged 40 years and older
CTR20262773Phase 2Active
- Sponsor
- Hanker Biopharma
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by Hanker Biopharma. Started Jul 2026; status: active.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on CTR20262773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262773.